Literature DB >> 20354540

Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.

Eitan Amir1, Alberto Ocaña, Bostjan Seruga, Robert Josse, Mark Clemons.   

Abstract

The addition of zoledronic acid to aromatase inhibitors is associated with improved bone mineral density, but not with an effect on clinically-meaningful end points such as fractures. The oncology community should prioritize the design of trials evaluating more relevant end points, such as fragility fracture risk, for treatment-induced bone loss and critically assess the effects of such treatment on breast cancer survival.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20354540     DOI： 10.1038/nrclinonc.2010.19

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  6 in total

1.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

2.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

3.  Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

Authors:  Adam M Brufsky; Linda D Bosserman; Richard R Caradonna; Barbara B Haley; C Michael Jones; Halle C F Moore; Lixian Jin; Ghulam M Warsi; Solveig G Ericson; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2009-05       Impact factor: 3.225

Review 4.  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

Authors:  E Seeman
Journal:  Bone       Date:  2007-06-26       Impact factor: 4.398

5.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Authors:  Georgiana K Ellis; Henry G Bone; Rowan Chlebowski; Devchand Paul; Silvana Spadafora; Judy Smith; Michelle Fan; Susie Jun
Journal:  J Clin Oncol       Date:  2008-08-25       Impact factor: 44.544

6.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Authors:  John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316
  6 in total
  6 in total

1.  Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

Authors:  Guenther G Steger; Rupert Bartsch
Journal:  Ther Adv Med Oncol       Date:  2011-09       Impact factor: 8.168

2.  Breast Cancer: Rank Ligand Inhibition.

Authors:  Rupert Bartsch; Guenther G Steger; Michael Gnant; Reinhard Ziebermayr
Journal:  Breast Care (Basel)       Date:  2010-10-15       Impact factor: 2.860

Review 3.  Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.

Authors:  Stéphanie Gaillard; Vered Stearns
Journal:  Breast Cancer Res       Date:  2011-03-14       Impact factor: 6.466

4.  Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole.

Authors:  Shengliang Sun; Fuchao Wang; Honglei Dou; Longqiang Zhang; Jiwen Li
Journal:  Onco Targets Ther       Date:  2016-10-05       Impact factor: 4.147

5.  Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience.

Authors:  Evelyne Bischof; Fabienne D Schwab; Elena Laura Georgescu Margarint; Céline Montavon; Iris Zünti; Anna Schollbach; Andreas Schötzau; Anna Hirschmann; Julia Landin; Christian Meier; Kurzeder Christian; Marcus Vetter
Journal:  Bone Rep       Date:  2021-12-11

Review 6.  Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting.

Authors:  Carmel Jacobs; Eitan Amir; Alexander Paterson; Xiaofu Zhu; Mark Clemons
Journal:  J Bone Oncol       Date:  2015-06-23       Impact factor: 4.072
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.